Evidence mapPaperPMID 29495516Full record

Trial reportNutrients2018

Effects of a Carob-Pod-Derived Sweetener on Glucose Metabolism.

Carmen Lambert, Judit Cubedo, Teresa Padró, Gemma Vilahur, Sergi López-Bernal, Milagros Rocha, Antonio Hernández-Mijares, Lina Badimon

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Nutrients, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Carob (Nutrients · 2026
    Review
  4. Evaluation of Commercial Carob Syrups (Foods (Basel, Switzerland) · 2025
    Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Supplementation with a Carob (Antioxidants (Basel, Switzerland) · 2020
    Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Carmen LambertProgram ICCC-Cardiovascular Research Center, Institut de Reserca, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, 08025 Barcelona, Spain. clambert@santpau.cat.
Judit CubedoProgram ICCC-Cardiovascular Research Center, Institut de Reserca, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, 08025 Barcelona, Spain. jcubedo@santpau.cat.
Teresa PadróProgram ICCC-Cardiovascular Research Center, Institut de Reserca, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, 08025 Barcelona, Spain. tpadro@santpau.cat.
Gemma VilahurProgram ICCC-Cardiovascular Research Center, Institut de Reserca, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, 08025 Barcelona, Spain. gvilahur@santpau.cat.
Sergi López-BernalProgram ICCC-Cardiovascular Research Center, Institut de Reserca, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, 08025 Barcelona, Spain. slopezb@santpau.cat.
Milagros RochaService of Endocrinology, University Hospital Dr Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), 46020 Valencia, Spain. Milagros.Rocha@uv.es.
Antonio Hernández-MijaresService of Endocrinology, University Hospital Dr Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), 46020 Valencia, Spain. hernandez_antmij@gva.es.ORCID 0000-0003-4099-1905
Lina BadimonProgram ICCC-Cardiovascular Research Center, Institut de Reserca, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, 08025 Barcelona, Spain. lbadimon@santpau.cat.ORCID 0000-0002-9162-2459
Instituto de Salud Carlos III · ESHospital de Sant Pau · ESFundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · ESUniversitat de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with type 2 diabetes mellitus (T2DM) have a higher incidence of cardiovascular (CV) events. The ingestion of high-glycemic index (GI) diets, specially sweetened beverage consumption, has been associated with the development of T2DM and CV disease.

objectiveWe investigated the effects of the intake of a sweetened beverage, obtained from natural carbohydrates containing pinitol (PEB) compared to a sucrose-enriched beverage (SEB) in the context of impaired glucose tolerance (IGT) and diabetes.

methodsThe study was divided in three different phases: (1) a discovery phase where the plasma proteomic profile was investigated by 2-DE (two-dimensional electrophoresis) followed by mass spectrometry (matrix-assisted laser desorption/ionization time-of-flight-MALDI-TOF/TOF) in healthy and IGT volunteers; (2) a verification phase where the potential mechanisms behind the observed protein changes were investigated in the discovery cohort and in an additional group of T2DM volunteers; and (3) the results were validated in a proof-of-concept interventional study in an animal model of diabetic rats with complementary methodologies.

resultsSix weeks of pinitol-enriched beverage (PEB) intake induced a significant increase in two proteins involved in the insulin secretion pathway, insulin-like growth factor acid labile subunit (IGF1BP-ALS; 1.3-fold increase;

conclusionsOur results suggest that the substitution of a common sugar source, such as sucrose, by a naturally-based, pinitol-enriched beverage induces changes in the insulin secretion pathway that could help to reduce blood glucose levels by protecting β-cells and by stimulating the insulin secretion pathway. This mechanism of action could have a relevant role in the prevention of insulin resistance and diabetes progression.

Indexed as

AdolescentAdultAgedAnimalsBeveragesBlood GlucoseBody Mass IndexComplement C4aDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Disease Models, AnimalDouble-Blind MethodFabaceaeGlucose IntoleranceGlycated HemoglobinHealthy VolunteersBlood GlucoseComplement C4aGlycated HemoglobinInositolInsulinInsulin-Like Growth Factor INutritive SweetenerspinitolPlant ExtractsC4A complementimpaired glucose toleranceinsulin-like growth factorsweetenertype 2 diabetes mellitus

Identifiers

PMID29495516
PMCPMC5872689
OpenAlexW2793854482

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.